Patents by Inventor Heather Raymon

Heather Raymon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Cancer with TOR Kinase Inhibitors
    Publication number: 20230338370
    Abstract: Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer.
    Type: Application
    Filed: October 28, 2022
    Publication date: October 26, 2023
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20230158035
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, Jingjing Zhao
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11590139
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: February 28, 2023
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20220273650
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: October 7, 2021
    Publication date: September 1, 2022
    Inventors: Shuichan XU, Kristen Mae HEGE, Antonia LOPEZ-GIRONA, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210371522
    Abstract: CD47 antibodies that specifically inhibit the interaction between CD47 and the CD47-signal regulatory protein alpha (SIRP?) but not the interaction between CD47 and thrombospondin-1 (TSP-1), and methods of using these monoclonal antibodies as therapeutics are provided.
    Type: Application
    Filed: August 2, 2021
    Publication date: December 2, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Pilgrim Jackson, Laure Escoubet, Kandasamy Hariharan, Michael Burgess, Kristen Hege, Heather Raymon, Piu Wong
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 11166950
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20210128565
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: January 12, 2021
    Publication date: May 6, 2021
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10940152
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 9, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200255515
    Abstract: Integrin-associated protein (IAP or CD47) antibodies that specifically inhibit the interaction between CD47 and the CD47-signal regulatory protein alpha (SIRPa) but not the interaction between CD47 and thrombospondin-1 (TSP-1), and methods of using these monoclonal antibodies as therapeutics are provided. Further disclosed are sequences of variable heavy chains and variable light chains of the antibodies provided.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 13, 2020
    Inventors: Victoria Sung, Pilgrim Jackson, Laure Escoubet, Kandasamy Hariharan, Michael Burgess, Kristen Hege, Heather Raymon, Piu Wong
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20200237768
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10646493
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 12, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10576085
    Abstract: Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 3, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: John F. Boylan, Gordon L. Bray, Ellen Filvaroff, Robert Hubbard, David Mikolon, Heather Raymon, Tao Shi, Tam M. Tran, Toshiya Tsuji, Lilly L. Wong, Shuichan Xu, Dan Zhu
  • Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
    Patent number: 10391092
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Toshiya Tsuji, Rama K. Narla, Kristen Mae Hege
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 10183019
    Abstract: Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: January 22, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Kristen Mae Hege
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20180235960
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 23, 2018
    Inventors: Shuichan XU, Kristen Mae HEGE, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY
    Publication number: 20180185361
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 5, 2018
    Inventors: HEATHER RAYMON, TOSHIYA TSUJI, RAMA K. NARLA, KRISTEN MAE HEGE
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 9980963
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 29, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Shuichan Xu, Antonia Lopez-Girona, Toshiya Tsuji, Kristen Mae Hege
  • Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
    Patent number: 9937169
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 10, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Toshiya Tsuji, Rama K. Narla, Kristen Mae Hege
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9937170
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 10, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • Methods for treating cancer using TOR kinase inhibitor combination therapy
    Patent number: 9782427
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor having the following formula (I): and an effective amount of a cytidine analog, such as 5-azacytidine, to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Heather Raymon